Clinical Trial of Ixekizumab for Psoriatic Arthritis Shows Positive Results

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

1. Mease PJ, van der Heidje D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: Results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2016 Aug 23. pii: annrheumdis-2016-209709. doi: 10.1136/annrheumdis-2016-209709. [Epub ahead of print]